-
1.发明申请公开(公告)号：US20140160709A1
公开(公告)日：2014-06-12
申请号：US14236838
申请日：2012-08-03
CPC分类号： H05K7/026 , H01R12/716 , H01R24/50 , H05K1/141 , H05K3/0008 , H05K3/308 , H05K13/04 , H05K2201/10189 , H05K2201/10371 , H05K2201/10803 , Y10T29/4913
摘要： Provided is a tuner module including a tuner module main body involving a tuner board, a first leg projected from the tuner module main body and to be inserted into a first hole formed on a circuit board main body, a second leg projected from the tuner module main body and to be inserted into a second hole formed on the circuit board main body, the second leg being shorter than the first leg, and a signal terminal projected from the tuner board and to be inserted into a third hole formed on the circuit board main body, the signal terminal being shorter than the second leg. A taper is formed on at least tip end parts of the first leg and the second leg.
摘要翻译： 提供了一种调谐器模块，包括：调谐器模块主体，包括调谐器板;从调谐器模块主体突出并插入形成在电路板主体上的第一孔中的第一支脚;从调谐器模块 主体并插入到形成在电路板主体上的第二孔中，第二腿短于第一腿部，以及从调谐器板突出并插入形成在电路板上的第三孔中的信号端子 主体，信号端子比第二支腿短。 在第一腿部和第二腿部的至少前端部分上形成锥形部。
-
公开(公告)号：US20060084618A1
公开(公告)日：2006-04-20
申请号：US10540864
申请日：2003-12-25
CPC分类号： C12N15/85 , C07K14/4702 , C12N2830/001 , C12N2830/008 , C12N2830/85 , G01N33/74
摘要： The present invention relates to a DNA having a promoter region containing regulatory sequences of human adiponectin gene, transformants transformed with the DNA, a screening method of a compound which can enhance the human adiponectin promoter activity, which the transformants are used, and the screening kit, and a screening method of a preventive/therapeutic medicine for syndromes such as Syndrome X, metabolic syndrome, multiple risk factor syndrome, insulin resistant syndrome, deadly quartet, and visceral fat syndrome, metabolic disorders such as diabetes, obesity, hypercholesterolemia, and hyperlipoproteinemias, hyperlipidemia, arteriosclerosis, hypertonia, circulatory system disease, and hyperphagia and a pharmaceutical composition obtained by using them.
-
公开(公告)号：US20100204191A1
公开(公告)日：2010-08-12
申请号：US12601998
申请日：2008-01-07
CPC分类号： C07J9/00 , A61K31/575
摘要： The present invention provides a VDR ligand which does not induce hypercalcemia that is an adverse reaction of a vitamin D3 preparation; and a composition which comprises lithocholic acid propionate, a salt thereof, a solvate thereof, or a prodrug thereof.
摘要翻译： 本发明提供了不诱导作为维生素D3制剂的不良反应的高钙血症的VDR配体; 以及包含丙酸铅胆碱，其盐，其溶剂合物或其前药的组合物。
-
公开(公告)号：US09278992B2
公开(公告)日：2016-03-08
申请号：US12601998
申请日：2008-01-07
IPC分类号： C07J9/00 , A61K31/56 , A61K31/575
CPC分类号： C07J9/00 , A61K31/575
摘要： The present invention provides a VDR ligand which does not induce hypercalcemia that is an adverse reaction of a vitamin D3 preparation; and a composition which comprises lithocholic acid propionate, a salt thereof, a solvate thereof, or a prodrug thereof.
摘要翻译： 本发明提供了不诱导作为维生素D3制剂的不良反应的高钙血症的VDR配体; 以及包含丙酸铅胆碱，其盐，其溶剂合物或其前药的组合物。
-
公开(公告)号：US07585623B2
公开(公告)日：2009-09-08
申请号：US10540864
申请日：2003-12-25
CPC分类号： C12N15/85 , C07K14/4702 , C12N2830/001 , C12N2830/008 , C12N2830/85 , G01N33/74
摘要： The present invention relates to a DNA having a promoter region containing regulatory sequences of human adiponectin gene, transformants transformed with the DNA, a screening method of a compound which can enhance the human adiponectin promoter activity, which the transformants are used, and the screening kit, and a screening method of a preventive/therapeutic medicine for syndromes such as Syndrome X, metabolic syndrome, multiple risk factor syndrome, insulin resistant syndrome, deadly quartet, and visceral fat syndrome, metabolic disorders such as diabetes, obesity, hypercholesterolemia, and hyperlipoproteinemias, hyperlipidemia, arteriosclerosis, hypertonia, circulatory system disease, and hyperphagia and a pharmaceutical composition obtained by using them.
摘要翻译： 本发明涉及具有包含人脂连蛋白基因调控序列的启动子区域的DNA，用DNA转化的转化体，能够增强人类脂联素启动子活性的化合物的筛选方法，以及筛选试剂盒 ，综合征X，代谢综合征，多发危险因素综合征，胰岛素抵抗综合征，致命四重奏和内脏脂肪综合征等综合征的预防/治疗药物的筛选方法，糖尿病，肥胖症，高胆固醇血症和高脂蛋白血症等代谢性疾病 ，高脂血症，动脉硬化，高渗，循环系统疾病和食欲过盛以及通过使用它们获得的药物组合物。
-
6.发明授权Pharmaceutical composition for the treatment of leukemia containing 9-cis-retinoic acid-.alpha.-tocopherol ester 失效用于治疗含有9-顺式 - 视黄酸-α-生育酚酯的白血病的药物组合物
公开(公告)号：US5929057A
公开(公告)日：1999-07-27
申请号：US92143
申请日：1998-06-05
IPC分类号： A61K31/355 , A61K31/59 , A61K31/20
CPC分类号： A61K31/355 , A61K31/59
摘要： 9-Cis-retinoic acid-.alpha.-tocopherol esters, pharmaceutical compositions containing the same and use of the same as a medicine for the treatment of leukemia, in particular, the remission of leukemia are provided and a combined use of a 9-cis-retinoic acid-.alpha.-tocopherol ester and either 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid exhibits a synergistic effect in the treatment of leukemia without any side effects caused by 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid.
摘要翻译： 提供9-顺式视黄酸-α-生育酚酯，含有该组合物的药物组合物，以及用于治疗白血病药物，特别是白血病缓解的药物组合物，并结合使用9-顺式 - 视黄酸-α-生育酚酯和1α，25-二羟基维生素D3或9-顺式 - 视黄酸在治疗白血病中表现出协同效应，而没有由1α，25-二羟基维生素D 3或9-顺式 - 视黄酸引起的任何副作用， 视黄酸。
-
公开(公告)号：US09018194B2
公开(公告)日：2015-04-28
申请号：US14002502
申请日：2012-03-01
申请人： Makoto Makishima , Sachiko Yamada , Antonio Mourino , Hiroaki Tokiwa , Takeru Kudo , Yusuke Watarai , Kazuki Maekawa
发明人： Makoto Makishima , Sachiko Yamada , Antonio Mourino , Hiroaki Tokiwa , Takeru Kudo , Yusuke Watarai , Kazuki Maekawa
IPC分类号： A61K31/593 , C07C401/00
CPC分类号： C07C401/00 , C07C2601/14 , C07C2602/24 , C07C2603/74
摘要： The present invention provides a compound which functions as a selective vitamin D receptor modulator and has action-selectivity or tissue-selectivity such that it does not induce hypercalcemia but causes other effects. There is provided a compound represented by formula (I), a solvate thereof or a prodrug thereof. wherein m and n each independently represent 1 or 0; R represents a hydrogen atom or an alkyl group; Y represents an ethane-1,1-diyl group or an ethyne-1,2-diyl group; and Z1 represents a hydrogen atom and Z2 represents a hydroxyalkoxy group, or Z1 and Z2 jointly form a methylene group.
摘要翻译： 本发明提供了作为选择性维生素D受体调节剂起作用且具有动作选择性或组织选择性的化合物，使得其不诱导高钙血症而引起其他作用。 提供由式（I）表示的化合物，其溶剂合物或其前药。 其中m和n各自独立地表示1或0; R表示氢原子或烷基; Y表示乙-1,1-二基或乙炔-1,2-二基; Z1表示氢原子，Z2表示羟基烷氧基，Z1或Z2共同形成亚甲基。
-
公开(公告)号：US20140038925A1
公开(公告)日：2014-02-06
申请号：US14002502
申请日：2012-03-01
申请人： Makoto Makishima , Sachiko Yamada , Antonio Mourino , Hiroaki Tokiwa , Takeru Kudo , Yusuke Watarai , Kazuki Maekawa
发明人： Makoto Makishima , Sachiko Yamada , Antonio Mourino , Hiroaki Tokiwa , Takeru Kudo , Yusuke Watarai , Kazuki Maekawa
IPC分类号： C07C401/00
CPC分类号： C07C401/00 , C07C2601/14 , C07C2602/24 , C07C2603/74
摘要： The present invention provides a compound which functions as a selective vitamin D receptor modulator and has action-selectivity or tissue-selectivity such that it does not induce hypercalcemia but causes other effects. There is provided a compound represented by formula (I), a solvate thereof or a prodrug thereof. wherein m and n each independently represent 1 or 0; R represents a hydrogen atom or an alkyl group; Y represents an ethane-1,1-diyl group or an ethyne-1,2-diyl group; and Z1 represents a hydrogen atom and Z2 represents a hydroxyalkoxy group, or Z1 and Z2 jointly form a methylene group.
摘要翻译： 本发明提供了作为选择性维生素D受体调节剂起作用且具有动作选择性或组织选择性的化合物，使得其不诱导高钙血症而引起其他作用。 提供由式（I）表示的化合物，其溶剂合物或其前药。 其中m和n各自独立地表示1或0; R表示氢原子或烷基; Y表示乙-1,1-二基或乙炔-1,2-二基; Z1表示氢原子，Z2表示羟基烷氧基，Z1或Z2共同形成亚甲基。
-
公开(公告)号：US5827878A
公开(公告)日：1998-10-27
申请号：US884040
申请日：1997-06-27
IPC分类号： A61K31/355 , A61K31/59
CPC分类号： A61K31/355 , A61K31/59
摘要： 9-Cis-retinoic acid-.alpha.-tocopherol esters, pharmaceutical compositions containing the same and use of the same as a medicine for the treatment of leukemia, in particular, the remission of leukemia are provided and a combined use of a 9-cis-retinoic acid-.alpha.-tocopherol ester and either 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid exhibits a synergistic effect in the treatment of leukemia without any side effects caused by 1.alpha.,25-dihydroxyvitamin D.sub.3 or 9-cis-retinoic acid.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.024 秒)